Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil
Authors:
- Marko PhernambucqMPMarko Phernambucq
- Pilar Martinez-MartinezPMPilar Martinez-Martinez
- Marc H. De BaetsMBMarc H. De Baets
- Mario LosenMLMario Losen
- 1 September 2008
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 201-202, 111-120
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Mycophenolate mofetil and myasthenia gravisLupus, 2005
- Pharmacokinetics of 6-Mercaptopurine in Patients with Inflammatory Bowel DiseaseTherapeutic Drug Monitoring, 2004
- Immunoregulation in Experimental Autoimmune Myasthenia Gravis—about T Cells, Antibodies, and EndplatesAnnals of the New York Academy of Sciences, 2003
- Mycophenolate Mofetil: A New Immunosuppressive ApproachSuccessful Treatment in a Case of Myasthenia gravis Associated with Incomplete Lupus erythematosus Syndrome and Hepatitis C Virus InfectionEuropean Neurology, 2001
- Mycophenolate mofetil for myasthenia gravis: An open-label pilot studyNeurology, 2001
- Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseasesNeurology, 2001
- Mycophenolate mofetil and its mechanisms of actionImmunopharmacology, 2000
- MYCOPHENOLIC ACID INCREASES APOPTOSIS, LYSOSOMES AND LIPID DROPLETS IN HUMAN LYMPHOID AND MONOCYTIC CELL LINESTransplantation, 1999
- Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetilTransplant Immunology, 1998
- Myasthenia GravisNew England Journal of Medicine, 1994